;

Bicycle Therapeutics Strengthens Senior Management Team

26/09/2017

Bicycle Therapeutics Strengthens Senior Management Team With Appointment of Maria Koehler, M.D., Ph.D., as Chief Medical Officer.

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the appointment of Maria Koehler, M.D., Ph.D., as Chief Medical Officer. Dr. Koehler will lead clinical strategy and oversee operational functions for Bicycle’s clinical development team to bring BT1718 and additional Bicycles to patients for the treatment of a range of cancers with poor survival outcomes.

“We are delighted to welcome Maria to the Bicycle leadership team. As Chief Medical Officer, she will play a pivotal role in furthering our mission to transform the treatment regimens for cancer and other diseases,” said Dr. Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “Maria has an exemplary track record, both as an oncology clinician and researcher, and as a drug development expert. We look forward to drawing on her breadth of experience in the development, registration and launch of oncology drugs. This expertise will prove invaluable as we continue to advance our broad pipeline of oncology therapeutics including our lead program, BT1718, and further evolve Bicycle Therapeutics as an integrated pharmaceutical company.”

Dr. Koehler, a trained oncologist with two decades of industry experience, joins Bicycle from Pfizer, where she was Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit. At Pfizer, Dr. Koehler was a key member of the oncology leadership team responsible for creating and coordinating innovative strategies for their oncology pipeline from early stage clinical trials through pivotal trials and product approval. Her accomplishments at Pfizer include leading development strategies for Palbociclib/IBRANCE, which was launched in 2015, and shaping the oncology portfolio. Prior to joining Pfizer, Dr. Koehler was the Group Leader for the Medicine Development Center of GlaxoSmithKline Oncology, and a Senior Medical Director for Oncology Research and Development at AstraZeneca. During her academic career, she was the Clinical Director of Bone Marrow Transplantation at University Hospital in Pittsburgh, PA, and Director of the Bone Marrow Transplant Program and Associate Professor at St. Christopher’s Hospital in Philadelphia, PA. She is a Board Certified Hematology/Oncology physician, and the author of more than 160 peer reviewed publications and book chapters. Dr. Koehler received her M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.

“This is a tremendous opportunity to contribute to the clinical development of Bicycles, which are a truly innovative new class of cancer treatment with broad potential to make a life-changing impact on patients with cancer,” said Dr. Koehler. “I’m eager to work with the Bicycle team to bring these unique and powerful therapies to patients.”

Click here for full press release.

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;